Patents by Inventor Taylor Schreiber

Taylor Schreiber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES
    Publication number: 20250145681
    Abstract: The present disclosure relates to, inter alia, compositions and pharmaceutical composition s, including heterologous chimeric proteins that find use, inter alia, in the treatment of diabetes, obesity, or metabolic syndrome.
    Type: Application
    Filed: November 18, 2024
    Publication date: May 8, 2025
    Inventors: Taylor SCHREIBER, George FROMM
  • FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES
    Publication number: 20250066446
    Abstract: The present disclosure relates to, inter alia, compositions and pharmaceutical composition s, including heterologous chimeric proteins that find use, inter alia, in the treatment of diabetes, obesity, or metabolic syndrome.
    Type: Application
    Filed: November 15, 2024
    Publication date: February 27, 2025
    Inventors: Taylor SCHREIBER, George FROMM
  • Compositions and methods for adjoining type I and type II extracellular domains as heterologous chimeric proteins
    Patent number: 12178847
    Abstract: The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: December 31, 2024
    Assignee: Kopfkino IP, LLC
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva, Neal Schilling
  • Fusion proteins for the treatment of cardiometabolic diseases
    Patent number: 12145975
    Abstract: The present disclosure relates to, inter alia, compositions and pharmaceutical compositions, including heterologous chimeric proteins that find use, inter alia, in the treatment of diabetes, obesity, or metabolic syndrome.
    Type: Grant
    Filed: March 8, 2024
    Date of Patent: November 19, 2024
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm
  • METHODS OF MAKING AND USING EXTRACELLULAR DOMAIN-BASED CHIMERIC PROTEINS
    Publication number: 20240368242
    Abstract: The present invention relates, inter alia, to compositions and methods, including chimeric proteins and combination therapies that find use in the treatment of disease, such as cancer and/or an inflammatory disease.
    Type: Application
    Filed: July 17, 2024
    Publication date: November 7, 2024
    Inventors: Taylor SCHREIBER, George FROMM, Suresh DE SILVA
  • COMBINATION THERAPIES WITH SIRP ALPHA-BASED CHIMERIC PROTEINS
    Publication number: 20240299492
    Abstract: The present disclosure relates to, inter alia, combinations of compositions which include chimeric proteins that find use in methods for treating disease, such as immunotherapies for cancer.
    Type: Application
    Filed: March 4, 2022
    Publication date: September 12, 2024
    Inventors: Taylor SCHREIBER, Suresh DE SILVA, George FROMM
  • Methods of making and using extracellular domain-based chimeric proteins
    Patent number: 12071465
    Abstract: The present invention relates, inter alia, to compositions and methods, including chimeric proteins and combination therapies that find use in the treatment of disease, such as cancer and/or an inflammatory disease.
    Type: Grant
    Filed: April 11, 2022
    Date of Patent: August 27, 2024
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES
    Publication number: 20240262881
    Abstract: The present disclosure relates to, inter alia, compositions and pharmaceutical composition s, including heterologous chimeric proteins that find use, inter alia, in the treatment of diabetes, obesity, or metabolic syndrome.
    Type: Application
    Filed: April 12, 2024
    Publication date: August 8, 2024
    Inventors: Taylor SCHREIBER, George Fromm
  • FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES
    Publication number: 20240218040
    Abstract: The present disclosure relates to, inter alia, compositions and pharmaceutical composition s, including heterologous chimeric proteins that find use, inter alia, in the treatment of diabetes, obesity, or metabolic syndrome.
    Type: Application
    Filed: March 8, 2024
    Publication date: July 4, 2024
    Inventors: Taylor SCHREIBER, George FROMM
  • TIGIT- AND LIGHT-BASED CHIMERIC PROTEINS
    Publication number: 20240190939
    Abstract: The present invention relates, inter alia, to compositions and methods, including TIGIT- and/or LIGHT-based chimeric proteins that find use in the treatment of disease, such as cancer and an inflammatory disease.
    Type: Application
    Filed: March 4, 2024
    Publication date: June 13, 2024
    Inventors: Taylor SCHREIBER, George FROMM, Suresh DE SILVA
  • GAMMA DELTA T-CELL COSTIMULATION
    Publication number: 20240148828
    Abstract: The present disclosure relates, inter alia, to compositions and methods, including heterodimeric proteins, including a heterodimeric protein comprising BTN2A1/3A1-Fc- and an scFv that specifically binds to a cancer targeting domain, that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity.
    Type: Application
    Filed: March 16, 2022
    Publication date: May 9, 2024
    Inventors: Taylor SCHREIBER, Suresh DE SILVA, George FROMM, Anne LAI
  • MUTANT PD-1 EXTRACELLULAR DOMAINS
    Publication number: 20240141014
    Abstract: The current disclosure relates to, inter alia, mutant derivatives of PD-1 protein. The current disclosure also relates to compositions and methods that find use in the treatment of diseases, such as immunotherapies for cancer and autoimmunity.
    Type: Application
    Filed: March 3, 2022
    Publication date: May 2, 2024
    Inventors: Taylor SCHREIBER, Suresh DE SILVA, George FROMM
  • FLT3L-BASED CHIMERIC PROTEINS
    Publication number: 20240122983
    Abstract: The present invention relates, inter alia, to compositions and methods, including chimeric proteins comprising an extracellular domain of FMS like tyrosine kinase 3 ligand (FLT3L) and an extracellular domain of a Type II transmembrane protein that find use in the treatment of disease, such as cancer.
    Type: Application
    Filed: December 26, 2023
    Publication date: April 18, 2024
    Inventors: Taylor SCHREIBER, George FROMM, Suresh DE SILVA
  • VSIG8-BASED CHIMERIC PROTEINS
    Publication number: 20240067698
    Abstract: The present invention relates, in part, to, chimeric proteins which include the extracellular domain of V-set and immunoglobulin domain-containing protein 8 (VSIG8) and their use in the treatment of diseases, such as immunotherapies for cancer and/or inflammatory diseases.
    Type: Application
    Filed: October 24, 2023
    Publication date: February 29, 2024
    Inventors: Taylor SCHREIBER, George Fromm, Suresh De Silva
  • FLT3L-based chimeric proteins
    Patent number: 11896618
    Abstract: The present invention relates, inter alia, to compositions and methods, including chimeric proteins comprising an extracellular domain of FMS like tyrosine kinase 3 ligand (FLT3L) and an extracellular domain of a Type II transmembrane protein that find use in the treatment of disease, such as cancer.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: February 13, 2024
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • METHODS OF TREATING CANCER USING TIGIT-AND LIGHT-BASED CHIMERIC PROTEINS
    Publication number: 20240016892
    Abstract: The present disclosure relates, inter alia, to compositions and methods, including chimeric proteins that find use in the treatment of disease, and to detection and treatment of drug resistant cancer using chimeric proteins.
    Type: Application
    Filed: December 3, 2021
    Publication date: January 18, 2024
    Inventors: Taylor SCHREIBER, George FROMM, Suresh DE SILVA
  • METHOD OF DETERMINING RESISTANCE TO CHECKPOINT INHIBITOR THERAPIES
    Publication number: 20240011101
    Abstract: The current disclosure relates to animal models, methods for screening and testing of an anti-cancer drug candidates, and to methods for treatment, evaluating efficacy of cancer treatment, and selecting patients for cancer therapy.
    Type: Application
    Filed: December 3, 2021
    Publication date: January 11, 2024
    Inventors: Taylor SCHREIBER, George FROMM, Suresh DE SILVA
  • HOMODIMERIC AND HETERODIMERIC PROTEINS COMPRISING BUTYROPHILIN
    Publication number: 20230416333
    Abstract: The present disclosure relates, inter alia, to compositions and methods, including heterodimeric proteins and chimeric proteins comprising portions of butyrophilin family of proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity.
    Type: Application
    Filed: April 14, 2021
    Publication date: December 28, 2023
    Inventors: Taylor SCHREIBER, George FROMM, Suresh DE SILVA
  • METHODS OF IDENTIFYING GAMMA DELTA T CELL-MODULATING AGENTS
    Publication number: 20230408523
    Abstract: The present invention relates to, in part, methods that are useful for cancer treatment, and methods for selecting personalized treatment regimens.
    Type: Application
    Filed: November 18, 2021
    Publication date: December 21, 2023
    Inventors: George FROMM, Suresh DE SILVA, Taylor SCHREIBER
  • VSIG8-based chimeric proteins
    Patent number: 11834488
    Abstract: The present invention relates, in part, to, chimeric proteins which include the extracellular domain of V-set and immunoglobulin domain-containing protein 8 (VSIG8) and their use in the treatment of diseases, such as immunotherapies for cancer and/or inflammatory diseases.
    Type: Grant
    Filed: November 1, 2021
    Date of Patent: December 5, 2023
    Assignee: Shattuck Labs
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva